Industry groups pushed for stronger competitiveness incentives under the EU Biotech Act framework, arguing current provisions are insufficient to restore Europe’s position in biopharma. The call emphasizes incentives across the full lifecycle—spanning academic research, clinical development, manufacturing, and commercialization—rather than incremental adjustments. Companies and stakeholders said policy design needs to reduce development and commercialization risk to keep capital and innovation from flowing elsewhere.